How to Read a Peptide COA

First establish what the document says it tested. Compare the compound or product name, form, quantity or concentration, vendor, lot or batch identifier, and dates with the item the certificate is being used to describe. A report for the same peptide but a different batch is historical context, not evidence for the batch in front of you.

“Received,” “tested,” “completed,” “reported,” and “released” are not synonyms. A useful certificate labels the event. Do not turn a report date into a test date or a test date into an expiration date.

FDA's Q7A guidance describes an API certificate as listing the material, batch, tests, acceptance limits, numerical results, and issuing organization. It is a manufacturing guidance, not a blanket rule for every retail certificate, but it is a useful model. See Q7A section 11.4.

Method names alone are not results. Look for the procedure or reference, specification, units, numerical result, and indication that the method was fit for its intended purpose. The FDA's Q2(R2) guidance explains why an analytical procedure is validated against its intended use.

An HPLC chromatogram separates detected signals into peaks. A reported area percentage commonly expresses one peak's share of the integrated signal under that method. That can be useful for a purity or impurity question, but it is not automatically the mass of peptide in the container.

Read the detector, method reference, sample preparation, reference material, system-suitability information, peak assignment, integration, and calculation when available. A chromatogram image without a result table is not a complete certificate.

Mass spectrometry can support identity when observed information is consistent with the expected molecule. How strong that evidence is depends on the method, instrument, reference, sample, and interpretation. A molecular-mass match does not make every other peak disappear and does not say how many milligrams were in the original container.

A quantitative content or assay result needs its own calibrated procedure, units, and result. If “10 mg” appears only in the product title, sample label, or requested specification, treat it as the stated target until the report clearly identifies it as a measured result.

A content or assay result compares the measured amount to the labeled claim. If the label says 10 mg and the assay says 8.5 mg, that is under-potent. If the label says 10 mg and the assay says 12 mg, that is over-potent. Both are deviations from the stated specification. The FDA's Q6A specifications guidance describes how acceptance criteria define upper and lower limits; results outside either end fail the specification.

Over-potency is not a bonus. It means the vial does not match the label. Dosing assumptions based on the labeled amount would be incorrect. If the specification is 10 mg and the result is 12 mg, the vial contains more than expected. That is not "extra quality" — it is a mismatch that affects how much you draw per dose if you are calculating from the label claim.

Under-potency means less than the labeled amount. That is also a mismatch. A result of 0% or "not detected" is a different situation: it means the test did not find the expected compound at all under the stated method, which raises identity and sourcing questions, not just quantity questions.

Read the specification, the result, and the units together. A passing result means the result fell within the stated acceptance range. A failing result means it did not. Both over and under can be fails if they exceed the allowed tolerance. For more on interpreting COA results in context, see the Peptide COA Database.

Chemical purity does not imply sterility. A sterility result addresses growth of viable microorganisms under a stated test. A bacterial endotoxin result addresses endotoxin under a separate procedure. Neither is answered by an HPLC or mass-spectrometry result.

The FDA's Q6A specifications guidance lists sterility and endotoxin or pyrogen as separate tests for parenteral drug products. The FDA endotoxin testing guidance likewise treats method, product-specific suitability, and acceptance criteria as material parts of the result.

A lot number connects records only when the identifiers match. Check punctuation, prefixes, suffixes, product form, and quantity. If a vendor page links one generic certificate across multiple products or lots, the document should explain that scope.

Chain of custody asks who selected the sample, where it came from, whether it was sealed, who handled it, and whether the result can be traced back to the product being described. Vendor-submitted testing and independently purchased testing provide different sampling evidence.

A laboratory lookup, QR code, or verification key may confirm that a report exists in the laboratory's system. It still does not prove that an unobserved retail vial came from the tested sample.

FDA's Import Alert 66-80 is a detention-without-physical-examination (DWPE) policy for GLP-1 receptor agonist bulk drug substances. The "Green List" names firms and products that appear to meet cGMP criteria for exclusion from DWPE. Being on the list documents apparent manufacturing compliance for that firm and product — it is not a purity contest.

A COA or marketing page may name a manufacturer, but that does not prove the retail vial came from that facility. Relabeling and re-labeler chains are common; the custody question is whether the lot connects to the named manufacturer and whether that manufacturer's documented controls apply to the vial in front of you.

Geography ("China," "USA," "factory direct") is not the test. FDA's import alert FAQ explains what Red, Green, and Yellow lists mean — they are about documented CGMP appearance, not country of origin. A claim of origin does not establish chain of custody, matching analytical tests, or vial-level traceability.

"Third-party tested" is a marketing phrase, not a result. It may mean a vendor sent a sample to an outside laboratory. It does not tell you which tests were performed, what the results were, or whether the tested sample represents the vial you have.

HPLC and mass spectrometry can support identity, approximate amount, and chemical purity of the sampled vial. They do not answer sterility, endotoxin, or whether every unit in a batch matches the sample. Those are separate quality attributes requiring separate procedures.

A forged or reused COA is still a PDF. A laboratory lookup or QR code that finds a report in a lab system only proves a report exists, not that the retail vial was the sample. FDA warning letters and enforcement records are a different dataset than a vendor COA; checking a lot against FDA recall or enforcement records is not the same as reading a certificate.

End with an evidence ledger. Record the supported fields and keep the unanswered questions visible.

1. 01Product and compound match
2. 02Lot or batch match
3. 03Sample and report dates
4. 04Laboratory and report identifier
5. 05Test methods performed
6. 06Specifications and units
7. 07Numerical results or pass/fail wording
8. 08Sample-source and custody information
9. 09Signature or authorization
10. 10Missing quality attributes

For the broader hierarchy of labels, prescription information, lot records, expiration dates, beyond-use dates, and COAs, read How to Read Peptide Product Documentation. To see these fields in our public evidence index, visit the Peptide COA Database.